Gene Therapy

個数:

Gene Therapy

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 48 p.
  • 言語 ENG
  • 商品コード 9780805338195

Full Description

Will gene therapy one day become the ultimate application of genetic technology? Gene Therapy, the newest booklet in the Special Topics in Biology Series, addresses this question by exploring gene therapy as a complex technology for delivering therapeutic genes as a way to treat and cure human genetic diseases. Author Mary Colavito provides an overview of the basic science involved in gene therapy methods and chronicles the history of gene therapy by discussing successful and ongoing gene therapy treatments as well as adverse outcomes in some cases of gene therapy. Also discussed are challenges that must be overcome for gene therapy to become a more reliable and readily accessible approach for treating a multitude of genetic diseases that affect humans. A list of web resources and relevant print publications are provided at the end of this Special Topics Booklet from Benjamin Cummings.

Contents

Realizing the Promise of Gene Therapy: Successes, Setbacks and Challenges

  

Methods Currently Employed



Identifying a disease that is likely to respond to gene therapy
Isolating a functional copy of the gene
Incorporating the gene into a carrier (vector)
Delivering the gene
Incorporating the Gene into a Chromosome
Determining whether the gene product is produced

 Partial Successes and Ongoing Trials



Gene Therapy for Severe Combined Immune Deficiency (SCID)
Gene Therapy for Cystic Fibrosis
Gene Therapy for Canavan Disease

 Setbacks



Insufficient Numbers of Cells Producing the Gene Product (Andrew Gobea's therapy for SCID)
Immune Reactions Targeting Cells Carrying the Vector (death of Jesse Gelsinger after therapy for Ornithine 
Transcarbamylase Deficiency [OTC])
Inadvertent Activation of Cancer-Causing Genes by a Vector (development of leukemia in French patients treated for SCID)

Challenges



Safe and Effective Delivery of the Gene
Production of a sufficient amount of gene product
Achieving a lasting improvement for the patient

Future Approaches



Controlling the chromosomal region where the delivered gene is inserted
Targeting specific sites on chromosomes for gene integration
Preventing insertion near cancer-causing genes by using insulators
Alternate Delivery Methods to Avoid Complications with Vectors

Liposomes containing genes without the need for vectors
Nanoparticles packaging DNA molecules for entry through nuclear pores


Expanding the means for achieving the goals of gene therapy by exploring alternative ways to assist the cell in producing the functional gene product or blocking the formation of a harmful product

Correction of the patient's DNA
Regulating production of the gene product by methods that affect RNA      


RNA interference leading to degradation of specific RNAs

Antisense RNA preventing protein production
Correction of RNA, through control of splicing



 

最近チェックした商品